(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 November 2024 (21.11.2024)

WIPO | PCT

(10) International Publication Number
WO 2024/238787 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *A61P 37/02* (2006.01)
A61P 11/00 (2006.01) *C07K 16/28* (2006.01)

(21) International Application Number:
PCT/US2024/029683

(22) International Filing Date:
16 May 2024 (16.05.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/467,169 17 May 2023 (17.05.2023) US

(71) Applicant: **SYNDAX PHARMACEUTICALS, INC.** [US/US]; 35 Gatehouse Drive, Building D, Floor 3, Waltham, Massachusetts 02451 (US).

(72) Inventors: **ORDENTLICH, Peter**; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). **RADOJCIC, Vedran**; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US).

(74) Agent: **GUZZO, Catherine** et al.; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) **Title:** METHODS OF TREATING CHRONIC GRAFT-VERSUS-HOST DISEASE-RELATED BRONCHIOLITIS OBLITERANS SYNDROME USING AN ANTI-COLONY STIMULATING FACTOR 1 RECEPTOR ANTIBODY



FIG. 1

(57) **Abstract:** The present disclosure provides methods of treating chronic graft-versus-host disease (cGVHD)-related bronchiolitis obliterans syndrome using an antibody that binds to colony stimulating factor 1 receptor (CSF-1R).

[Continued on next page]

WO 2024/238787 A1

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*